Novartis Stock Earnings Estimates Raised by Zacks Research

Key Points

• Zacks Research raised Novartis’ FY2027 EPS estimate to $9.75 from $9.68, while forecasting $2.47 EPS for Q4 2027.
• Novartis reported quarterly EPS of $2.41 on revenue of $14.95 billion, with a 23.29% net margin and 38.56% return on equity.
• Analyst sentiment remains mixed, with six Buy ratings and ten Hold ratings producing a consensus Hold rating and a $153 target price; the stock recently opened at $145.49.

Novartis AG (NYSE:NVS - Free Report) - Investment analysts at Zacks Research increased their FY2027 earnings per share (EPS) estimates for Novartis in a research report issued to clients and investors on Friday, September 25th. Zacks Research analyst Team now anticipates that the company will earn $9.75 per share for the year, up from their prior estimate of $9.68. The consensus estimate for Novartis' current full-year earnings is $8.87 per share. Zacks Research also issued estimates for Novartis' Q4 2027 earnings at $2.47 EPS.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $14.95 billion for the quarter. Novartis had a return on equity of 38.56% and a net margin of 23.29%.

NVS has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft cut shares of Novartis from a "buy" rating to a "hold" rating in a research note on Tuesday, September 8th. HSBC upgraded shares of Novartis from a "reduce" rating to a "hold" rating and lifted their target price for the company from $123.00 to $136.00 in a research report on Thursday, September 10th. Citigroup reissued a "buy" rating on shares of Novartis in a research note on Wednesday, July 22nd. Royal Bank Of Canada started coverage on shares of Novartis in a research report on Tuesday, September 8th. They set a "sector perform" rating for the company. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Novartis in a research note on Friday, July 24th. Six equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Novartis has a consensus rating of "Hold" and a consensus target price of $153.00.

Novartis Trading Up 0.0%

Shares of NVS stock opened at $145.49 on Monday. Novartis has a 1-year low of $121.57 and a 1-year high of $170.46. The company has a market cap of $277.62 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 2.81 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a current ratio of 0.86 and a quick ratio of 0.67. The stock has a 50 day simple moving average of $151.67 and a 200-day simple moving average of $151.25.

Hedge Funds Weigh In On Novartis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NVS. Auto Owners Insurance Co grew its position in Novartis by 13,687.0% in the fourth quarter. Auto Owners Insurance Co now owns 4,628,296 shares of the company's stock worth $638,103,000 after acquiring an additional 4,594,726 shares during the period. WCM Investment Management LLC acquired a new position in shares of Novartis in the 1st quarter valued at $220,004,000. Arrowstreet Capital Limited Partnership acquired a new position in shares of Novartis in the 4th quarter valued at $108,638,000. Franklin Resources Inc. grew its holdings in shares of Novartis by 10.3% during the 4th quarter. Franklin Resources Inc. now owns 4,479,307 shares of the company's stock worth $617,562,000 after purchasing an additional 419,988 shares during the period. Finally, Bank of America Corp DE increased its position in shares of Novartis by 9.1% during the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company's stock worth $758,067,000 after purchasing an additional 413,778 shares during the last quarter. Institutional investors and hedge funds own 13.12% of the company's stock.

About Novartis

Novartis AG NYSE: NVS is a Switzerland-based pharmaceutical company focused on discovering, developing and commercializing innovative medicines. The company's portfolio addresses major disease areas including cardiovascular, renal and metabolic conditions, immunology, neuroscience, oncology and hematology.

Novartis markets medicines such as Entresto for certain heart conditions, Cosentyx for inflammatory diseases, Kisqali for breast cancer, Kesimpta for multiple sclerosis, Leqvio for cholesterol management, Pluvicto for certain prostate cancers and Scemblix for chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.